Floatz logo

Therapeutic Asset Ratings

6,305 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
be-101
Hemophilia B
Be BiopharmaP1/2CC (45)
Benmelstobart
Cancer
Jinming YuP1/2CC (45)
Benmelstobart
Melanoma
Beijing Tide Pharmaceutical Co., LtdP1/2CC (45)
Bet Bromodomain Inhibitor Zen-3694
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)P1/2CC (45)
bg1805
Acute Myeloid Leukemia
Guangzhou Bio-gene Technology Co., LtdP1/2CC (45)
bh-30643
Non-Small Cell Lung Carcinoma
BlossomHill TherapeuticsP1/2CC (45)
bi-1808
T-Cell Non-Hodgkin Lymphoma
BioInvent International ABP1/2CC (45)
Bicalutamide
Metastatic Neoplasm
Icahn School of Medicine at Mount SinaiP1/2CC (45)
Bifidobacterium Bifidum
Hepatocellular Carcinoma
Sun Yat-sen UniversityP1/2CC (45)
Biological Ntla-3001
Lung Disorder
Intellia TherapeuticsP1/2CC (45)
Blinatumomab
High Grade B-Cell Lymphoma
M.D. Anderson Cancer CenterP1/2CC (45)
Blinatumomab
High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement
M.D. Anderson Cancer CenterP1/2CC (45)
bmd006
Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP1/2CC (45)
Bms-936558-01
Head And Neck Squamous Cell Carcinoma
Bristol-Myers SquibbP1/2CC (45)
Bms 986253
Prostate Adenocarcinoma
Mark SteinP1/2CC (45)
BN104
Acute Myeloid Leukemia
Chen SuningP1/2CC (45)
bnt324
Lung Cancer
BioNTech SEP1/2CC (45)
bnt327
Lung Cancer
BioNTech SEP1/2CC (45)
Bortezomib
Li-Fraumeni Syndrome
Masonic Cancer Center, University of MinnesotaP1/2CC (45)
Bpi-1178
Hormone Receptor-Positive Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.P1/2CC (45)
br790
Cancer
Shanghai Gopherwood Biotech Co., Ltd.P1/2CC (45)
Brivestobart
Non-Small Cell Lung Carcinoma
Guangzhou Gloria Biosciences Co., Ltd.P1/2CC (45)
Brl-101
Beta Thalassemia
Bioray LaboratoriesP1/2CC (45)
bs006
Neoplasm
Binhui Biopharmaceutical Co., Ltd.P1/2CC (45)
Bsb-1001
Myelodysplastic Syndrome
BlueSphere Bio, IncP1/2CC (45)
Showing 3001 to 3025 of 6,305 assets
PreviousPage 121 of 253Next